A large international study has found that asundexian, an investigational anti-clotting medication, reduces the risk of a stroke in people who recently experienced a stroke or transient ischemic attack (TIA) caused by a clot ...
Apr 15, 2026
0
72
An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary late-breaking science ...
Feb 5, 2026
0
11
Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session Sept. 1 ...
Sep 2, 2024
0
33
The PACIFIC-Stroke trial has failed to reach its primary endpoint but in an exploratory analysis, inhibition of factor XIa with asundexian reduced recurrent ischemic stroke and transient ischemic attack (TIA) without increasing ...
Aug 29, 2022
0
69
Asundexian 50 mg administered to post-myocardial infarction patients inhibits factor XIa by more than 90% with no significant increase in bleeding, according to late breaking research presented in a Hot Line session on 28 ...
Aug 29, 2022
0
62
